Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009

Gramatzki, Dorothee; Dehler, Silvia; Rushing, Elisabeth J.; Zaugg, Kathrin; Höfer, Silvia; Yonekawa, Yasuhiro; Bertalanffy, Helmut; Valavanis, Anton; Korol, Dimitri; Rohrmann, Sabine; Pless, Miklos; Oberle, Joachim; Roth, Patrick; Ohgaki, Hideaki; Weller, Michael

doi:10.1002/cncr.30023

Cited by 76 publications

(36 citation statements)

References 32 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diffuse gliomas are the most common types of primary brain tumors [1]. Due to their infiltrative growth pattern they cannot be cured [2], and the median survival is up to approximately 15 years for patients with low-grade glioma (LGG) [3] and 10-12 months for patients with high-grade glioma (HGG) [4,5]. The incurable nature of diffuse gliomas thus makes preservation of quality of life a paramount factor to consider in treatment decision making.…”

Section: Introductionmentioning

confidence: 99%

Perioperative fatigue in patients with diffuse glioma

et al. 2020

View full text Add to dashboard Cite

Purpose Few studies have assessed fatigue in relation to glioma surgery. The purpose of this study was to explore the prevalence of pre-and postoperative high fatigue, perioperative changes, and factors associated with pre-and postoperative high fatigue in patients undergoing primary surgery for diffuse glioma. Methods A total of 112 adult patients were prospectively included. Patient-reported fatigue was assessed before and one month after surgery using the cancer-specific European Organization for Research and Treatment of Cancer questionnaire fatigue subscale. The scores were dichotomized as high fatigue (≥ 39) or low fatigue (< 39). A change in score of ≥ 10 was considered as a clinically significant change. Factors associated with pre-and postoperative high fatigue were explored in multivariable regression analyses. Results High fatigue was reported by 45% of the patients preoperatively and by 42% of the patients postoperatively. Female gender and low Karnofsky Performance Status (KPS) were associated with preoperative high fatigue, while postoperative complications, low KPS and low-grade histopathology were associated with postoperative high fatigue. In total 35/92 (38%) patients reported a clinically significant improvement of fatigue scores after surgery, 36/92 (39%) patients reported a clinically significant worsening of fatigue scores after surgery, and 21/92 (23%) patients reported no clinically significant change in fatigue scores after surgery. Patients with low-grade gliomas more often reported low fatigue before surgery and high fatigue after surgery, while patients with high-grade gliomas more often reported high fatigue before surgery and low fatigue after surgery. Conclusions Our findings indicate that fatigue is a common symptom in patients with diffuse glioma, both pre-and postoperatively. Perioperative changes were frequently seen. This is important knowledge when informing patients before and after surgery.

show abstract

Section: Introductionmentioning

confidence: 99%

Perioperative fatigue in patients with diffuse glioma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Glioblastoma is the most common primary brain tumor, with an annual incidence of 3.9 cases per 100,000 individuals in the Canton of Zurich ( 1 ) and the most aggressive among all gliomas. The standard of care includes radiotherapy plus concomitant and maintenance temozolomide chemotherapy (TMZ/RT→TMZ) ( 2 ), resulting in a median survival time of 16 months in clinical trial populations ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Interleukin-33 in human gliomas: Expression and prognostic significance

et al. 2016

Self Cite

View full text Add to dashboard Cite

Interleukin-33 (IL-33) is a nuclear and pleiotropic cytokine with regard to its cellular sources and its actions. IL-33 is involved in the pathogenesis of brain diseases. Several factors account for the tumorigenicity of human gliomas, including cytokines and their receptors. The present study assessed the expression and prognostic significance of IL-33 in human astroglial brain tumors. Protein levels of IL-33 were determined by immunohistochemistry using a tissue microarray containing 95 human gliomas. mRNA expression data of IL-33, as well as of its receptors, IL-1 receptor-like 1 protein and IL-1 receptor accessory protein (IL1RAcP), were obtained from The Cancer Genome Atlas database. IL-33 protein was expressed heterogeneously in tumor tissue, but was, however, not detected in normal brain tissue. There was no differential IL-33 protein expression by tumor grade, while IL-33 protein expression was associated with inferior survival in patients with recurrent glioblastomas. Interrogations of the TCGA database indicated that mRNA expression of IL-33 and the IL-33 receptors was heterogeneous, and that IL-33 and IL1RAcP mRNA levels were correlated with the tumor grade. Elevated IL-33 mRNA levels were associated with the inferior survival of glioblastoma patients. Therefore, IL-33 may play an important role in the pathogenesis and prognosis of human gliomas.

show abstract

“…We appreciate the feedback of Drs. Caldarella and Barchielli concerning our recent analysis of patterns of care and outcome among patients with glioblastoma diagnosed in the Canton of Zurich, Switzerland, from 2005 to 2009 . It is reassuring to us that our colleagues also report an improvement in outcome in their catchment area.…”

mentioning

confidence: 70%